This is the authors' abstract. We don't add key points for this paper.
Individuals with inflammatory rheumatic disease require special consideration with regard to coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many of these individuals are considered at-risk for serious infections due to their immunocompromised state resulting from their underlying immune conditions and use of targeted immune-modulating therapies such as biologics.1–4 However, some disease-modifying drugs commonly used to treat rheumatic diseases, such as hydroxychloroquine, are being investigated as potential therapies for COVID-19.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Gianfrancesco et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: